The Founding Angels Concept for the Targeted Foundation of Start-ups Background, Approach, Examples and Conclusions



8th Swiss Snow Symposium for Young Chemists

Untervaz, February 20, 2010

ETH

Eidgenössische Technische Hochschule Zürich Swiss Federal Institute of Technology Zurich



© 2010 FESTEL CAPITAL

1	Background and Challenge
2	Founding Angels Concept
3	Selected Biotech Examples
4	Experience and Learnings
5	Founding Angels Platform

There are two gaps between academic research and the commercialisation of the research results which have to be closed



© 2010 FESTEL CAPITAL





Current research at ETH Zurich investigated the possibility to close these gaps with new business models

Nanotechnology

Insufficient commercial success of nanotechnology in Germany

(Discussion with BMBF/Impulskreis Nanowelten and VDI)

Industrial Biotechnology

Commercialisation within industrial biotechnology research results too slow in Europe

(Discussions with BMBF and Europa Bio)

Research question

How can the foundation of start-ups improve the commercialisation of new technologies in early stages?

ETH

Eidgenössische Technische Hochschule Zürich Swiss Federal Institute of Technology Zurich

Department of Management, Technology and Economics (D-MTEC)

Chair of Technology and Innovation Management (Prof. Roman Boutellier)

Working Group Start-ups

Pharmaceutical R&D

Insufficient innovation capability in the medium-sized pharma industry in Germany

(Discussion with BPI and VfA)

R&D Spin-offs

R&D projects are often "crushed" and the results disappear in a "drawer"

(Discussion with various chemical and pharma companies)

© 2010 FESTEL CAPITAL

Real life examples show that the gaps can be closed by the targeted foundation of start-ups



© 2010 FESTEL CAPITAL

ESTEL CAPITAL

Creating a Better Future

Eidgenössische Technische Hochschule Zürich

Swiss Federal Institute of Technology Zurich



Founding Angels are engaged in very early phases and fill the gap between established business models within the start-up area



© 2	201) FES	TEL	CAP	ITAL
-----	-----	-------	-----	-----	------





I SOUTCES Public (stock market)	Advance Nanotech Arrowhead Research Corporation	Angle Technology XL TechGroup	 Very early stage engagement of Founding Angels is based on the right combination of Scientific understanding Business expertise Financial independence
Financia Private (investment fund, privately-held)	Molecular Manufacturing Enterprises	Arch Venture Partners Precede Technologies Proseed Capital Sanderling Ventures	 Team building competence Willing to take risks Important: Understanding of all relevant scientific/technical and commercial aspects
	Focus on nanotechnology Technoloc	Broader technological scope	

1	Background and Challenge
2	Founding Angels Concept
3	Selected Biotech Examples
4	Experience and Learnings
5	Founding Angels Platform



Our Founding Angels activities are focused on chemical / lifescience and physics related technology fields



© 2010 FESTEL CAPITAL



The definition of clear process phases provides a framework to manage the Founding Angel investments

Process Phases

- Phase 1 = Project sourcing: <u>Project opportunities</u> are sourced and evaluated to identify those which have the highest potential and the best fit
- Phase 2 = Foundation: A new company is formed and an agreement is signed with the technology partner (e.g. universities) providing rights regarding the relevant IP and other resources
- Phase 3 = Company structures: Effective and efficient company structures are built-up including <u>further R&D work</u> (as a rule done together with the technology partner in the starting phase)
- Phase 4 = Business development: Business development is established to find <u>co-operation partners</u> and to generate first revenues
- **Phase 5 = Exit strategy:** An exit strategy is developed and executed to sell the company or its assets within around 5 years to <u>established partners</u>

Eidgenössische Technische Hochschule Zürich Swiss Federal Institute of Technology Zurich



The Founding Angels investment strategy offers clear advantages due to its uniqueness

Investment Strategy

- Step 1: Identification of interesting markets with high potential where established companies are too slow or "conservative"
- Step 2: Understanding of the value chains and identification of bottleneck technologies with very focused investments to develop these technologies
- Step 3: Co-operation with / trade sale to established companies to use their marketing and production resources after the building-up of a strong IP position



> High risk diversification / relatively low total risk

The most attractive projects are identified with a well-structured selection process



> ~ 80 project ideas

© 2010 FESTEL CAPITAL



We evaluated around 20 projects between 2006 and 2007 and 6 of the most promising projects have been realised



© 2010 FESTEL CAPITAL



Five companies in the field of biotechnology have been founded over the last two years and an additional company is to be founded by the end of 2009





Selected Biotech Examples - Butalco

Butalco is focused on the development of second generation biofuels and other bio-based products

Overview Development and commercialisation of Hydrolysis yeast technology to produce second Biomass generation biofuels and other bio-based Yeast-based products **Biorefineries** BUTALCO Development of technologies in the field YEAST DESIGN of lignocellulose hydrolysis, fermentation technology and downstream processing together with partners Co-operation with producing companies Biofuels - Bioethanol but no own production facilities planned - Biobutanol - Other Molecules Wind energy company Volkswind GmbH Bio-based chemicals Bioactives as investor Drug discovery **Butalco GmbH, Huenenberg/Switzerland**

www.butalco.com

Technology Butanol Fermentation Butanol Glucose derivative BUTALCO Ethanol Pentoses Yeasts Organic ac Other sugars polymer Isoprenoie Drugs Fine Linids NADH. Glutathion. Glucan development BUTALCO Yeasts Yeast-based otein Expressio Drug Screening Assays Yeast Technology **Biofuel Technology** using C5 sugars using C5 and C6 sugars Production of biofuels by other microorganisms Hydrolysis of lignocellulose Downstream processing Fermentation technology BUTALCO with own research Engi-Biofuel Biofuel Biofue Feedstock Cellulose neering/ purifi-**BUTALCO** with research partner producfermen supply hydrolysis constructatior cation tion tion BUTALCO as co-operation partner



bio-based innovatior



Selected Biotech Examples - AlgMax

AlgMax is focused on technologies for the cultivation and usage of algae biomass grown in closed systems



www.festel.com

AlgMax Algae Power



Autodisplay Biotech is developing the autodisplay technology for biocatalysis and other applications



Autodisplay Biotech

Eidgenössische Technische Hochschule Zürich

Swiss Federal Institute of Technology Zurich

ESTEL

Creating a Better Future

APITAL

© 2010 FESTEL CAPITAL

BayGenetics is focused on the development of a Bacillus subtilis platform for protein and vaccine production



© 2010 FESTEL CAPITAL



Biotech Solutions

BayGenetics

ETH

1	Background and Challenge
2	Founding Angels Concept
3	Selected Biotech Examples
4	Experience and Learnings
5	Founding Angels Platform

© 2010 FESTEL CAPITAL





Important Aspects			
 All founders, including the Founding Angel, should receive the same equity share 	The engagement of a Founding Angel is based on the <u>right</u> combination of		
The Founding Angel like all other founders should <u>not receive any compensation</u> until the company reaches break-even	 business and start-up expertise/ experiences 		
• The Founding Angel should be in a position to give cash injections, if necessary, as shareholder loans (in order not to change the ownership structure)	 understanding of all relevant scientific/technical aspects understanding of all commercial implications 		
• The Founding Angel usually takes on the role as <u>interim CEO</u> , but should hand over the position to a full-time CEO as soon as possible	 team building competence willing to take own risks 		
• Very important is the "personal chemistry" between the partners (team spirit, team work, respect, trust)	financial independence		



The two most important success factors are reputation of the team and attractiveness of the area/topic



© 2010 FESTEL CAPITAL



The engagement as Founding Angel is a full-time job, if more investments are managed



© 2010 FESTEL CAPITAL



With small own investments it was possible to recruit significant third party investments and to build-up a 100 times higher book value



On average ownership of 30% of the start-ups

© 2010 FESTEL CAPITAL

5	Founding Angels Platform
4	Experience and Learnings
3	Selected Biotech Examples
2	Founding Angels Concept
1	Background and Challenge



The Founding Angels initiative is a non-profit platform to promote the business model

Initiators	Advisory Board	Partners
 Prof. Dr. Roman Boutellier, ETH Zurich 	 John Cheesemond, Member of the Supervisory Board, Cognis 	Best Excellence Rhein-Main
Dr. Gunter Festel, FESTEL CAPITAL	 Walter Groll, Member of the Board of Management, DekaBank 	• Forseo Freiburg
Dr. Berndt Samsinger, SE Swiss Equities	 Prof. Dr. Josef Nassauer, Chief Executive, Bayern Innovativ 	Fraunhofer UMSICHT UMSICHT
 Prof. Dr. Dirk Schiereck, European Business School, Oestrich-Winkel Prof. Dr. Max von Zedwitz 	 Dr. Achim Riemann, CEO of International Chemical Investors and previously CEO of Arthur D. Little in Central Europe 	 High-Tech Gründerfonds Life Science Center
AsiaCompete	 Thomas Schäfer, Senior Director New Business Development, Novozymes Dr. Klaus Warning, Business Angel with c-LEcta and previously 	 Dusseldorf Science4Life Universität Bayreuth Universität Düsseldorf
	Member of the Board at Hoechst Celanese and SGL Carbon	DUSSELDORF

Please visit www.founding-angels.com for further information

© 2010 FESTEL CAPITAL